Logo-apb
  Abstract View: 59

Research Article

Formulation, Development and Evaluation of Budesonide Oral Nano-sponges Using DOE Approach: In-vivo Evidences

Amarjit Salunke* ORCID logo, Neeraj Upmanyu

1 School of Pharmacy & Research (PIP & RC) People’s Campus, Karond-Bhanpur Bypass Road Bhanpur, Bhopal- 462037, M.P, India.

Abstract

Purpose: The prevalent types of idiopathic inflammatory bowel disease (IBD) are ulcerative colitis and Crohn’s disease, which affects a large number of populations. Budesonide (BUD) is a glucocorticoid with potent anti-inflammatory activity but low systemic efficacy because of high receptor affinity and rapid diversion. To overcome low efficacy and availability, a novel Budesonide nano-sponges was formulated using quasi- solvent diffusion and Eudragit S-100 as polymer. It was then investigated for the effect of process variables using Box-Behnken design.
Methods: The BUD Nano sponges were evaluated for particle size, particle size, polydispersity, percent drug entrapment, drug release pattern. The formulation was evaluated by an in vivo study using male Wistar rats and parameters such as clinical activity score (CAS), colon/body weight ratio (C/B ratio), macroscopic ulceration (damage score) activity were performed. Finally, histopathological examination was performed on colon tissue samples.
Results: The formulation showed better efficacy and availability as compared with the available formulations of budesonide, which indicates the good efficacy of the formulated nanosponges. The clinical activity score was attenuated by the formulated nanosponges in the Wistar rats. The colon to body weight ratio was significantly reduced as compared with the control formulation. The histopathology of colon treated with nanosponges showed normal structure and architecture of the colon.
Conclusion: The results of the present work confirmed the utility of Budesonide nano-sponges as novel carriers in management inflammatory bowel disease.
Keywords: Budesonide Nano-sponges, Colon Tissue, Box-Behnken design, Quasi-emulsion solvent, Inflammatory bowel disease, Eudragit S-100
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 59

Your browser does not support the canvas element.


PDF Download: 0

Your browser does not support the canvas element.

Submitted: 07 Feb 2020
Revision: 17 Jul 2020
Accepted: 05 Aug 2020
ePublished: 05 Aug 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)